Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design

por Mease, Kirsten M., Kimzey, Amy L., Lansita, Janice A.
Publicado 2017

A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats

por Sibley, Katherine, Chen, Jayson, Koetzner, Lee, Mendes, Odete, Kimzey, Amy, Lansita, Janice, Boulos, Ramiz A.
Publicado 2019

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

por Basarab, Gregory S., Kern, Gunther H., McNulty, John, Mueller, John P., Lawrence, Kenneth, Vishwanathan, Karthick, Alm, Richard A., Barvian, Kevin, Doig, Peter, Galullo, Vincent, Gardner, Humphrey, Gowravaram, Madhusudhan, Huband, Michael, Kimzey, Amy, Morningstar, Marshall, Kutschke, Amy, Lahiri, Sushmita D., Perros, Manos, Singh, Renu, Schuck, Virna J. A., Tommasi, Ruben, Walkup, Grant, Newman, Joseph V.
Publicado 2015

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

por Basarab, Gregory S., Kern, Gunther H., McNulty, John, Mueller, John P., Lawrence, Kenneth, Vishwanathan, Karthick, Alm, Richard A., Barvian, Kevin, Doig, Peter, Galullo, Vincent, Gardner, Humphrey, Gowravaram, Madhusudhan, Huband, Michael, Kimzey, Amy, Morningstar, Marshall, Kutschke, Amy, Lahiri, Sushmita D., Perros, Manos, Singh, Renu, Schuck, Virna J. A., Tommasi, Ruben, Walkup, Grant, Newman, Joseph V.
Publicado 2015